U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07529561) titled 'Efficacy of CL25216 on Hormonal Balance and Menstrual Health in Women With Primary Dysmenorrhea.' on April 08.
Brief Summary: This study is to evaluate the effects of CL25216 on hormonal balance and menstrual health in women with primary dysmenorrhea. Enrolled subjects will receive either CL25216 - 250 mg/day or placebo.
Study Start Date: April 13
Study Type: INTERVENTIONAL
Condition:
Primary Dysmenorrhea
Menstural Cramps
Intervention:
DIETARY_SUPPLEMENT: CL25216
CL25216: 250mg, One capsule a day after breakfast for 84 days.
OTHER: Placebo
One capsule a day after breakfast for 84 days.
Recruitment Status: NOT_YET_RECRUITI...